BUZZ-AstraZeneca: boosted by Liberum upgrade as Healthcare rallies

** AstraZeneca (Swiss: AZN.SW - news) +1%, second-top riser on FTSE 100 in volume

** Liberum upgrades to "buy" v "hold" - with stock down 8 pct YTD, trading around 5-mth lows, risk/reward going into a rich seam of catalysts is now strongly to the upside

** Four major immuno-oncology readouts in 2017 (incl. MYSTIC) plus key data on Acalabrutinib, Lynparza and Tagrisso there is 25-30% upside to Liberum's FV if positive

** European Healthcare among the region's worst performers in the last three months, with the sector having been at the fore of concerns surrounding US election outcome (Liberum: sector trade-off overdone, Trump a major positive)

** Old Mutual Global Investors' Simon Murphy has been buying Healthcare into weakness (GSK and AZN)

** Of MYSTIC, due 2017, PM said recently analysts expect shares up or down 10-15% on the day (positive outcome means possible $5 bln sales over next 5-10 yrs for a co that has $25 bln revenues, per PM)

** Healthcare +0.6% on Friday, one of only two European sectors in positive territory (Food & Beverages also up 0.6%)

** Swiss biotech group Actelion (LSE: 0QMN.L - news) top performer, +9.5%, on potential takeover by Johnson & Johnson (NYSE: JNJ - news) (Bloomberg report)

(RM (LSE: RM.L - news) : tricia.wright1.thomsonreuters.com@reuters.net)